Therapy Detail

Therapy Name DCC-2618
Therapy Description

DCC-2618 is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (PMID: 29439183).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
DCC-2618 KIT Inhibitor 48 PDGFR-alpha Inhibitor 7 DCC-2618 is a dual inhibitor of KIT and PDGFRa, resulting in growth inhibition and anti-tumor effects (PMID: 29439183).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown gastrointestinal stromal tumor not applicable DCC-2618 Phase I Actionable In a Phase I study, DCC-2618 treatment resulted in an overall response rate of 16% (16/99) in patients with drug resistant gastrointestinal stromal tumors, 71% (55/77) of analyzed patients harbored baseline KIT or PDGFRA activating mutations (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 11511-11511; NCT02571036). detail...
KIT D816Y mast cell neoplasm sensitive DCC-2618 Preclinical - Cell culture Actionable In a preclinical study, DCC-2618 inhibited proliferation of a mouse mastocytosis cell line expressing KIT K816Y in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2690). detail...
KIT mutant gastrointestinal stromal tumor predicted - sensitive DCC-2618 Phase I Actionable In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA). detail...
KIT amp PDGFRA amp glioblastoma multiforme sensitive DCC-2618 Phase I Actionable In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA). detail...
KIT exon 11 gastrointestinal stromal tumor predicted - sensitive DCC-2618 Preclinical - Cell line xenograft Actionable In a preclinical study, DCC-2618 inhibited Kit phosphorylation and tumor growth in a gastrointestinal stromal tumor cell line xenograft model harboring a KIT exon 11 deletion mutation (Cancer Res 2015;75(15 Suppl):Abstract nr 2690). detail...
KIT W557_K558del KIT Y823D gastrointestinal stromal tumor sensitive DCC-2618 Preclinical - Pdx Actionable In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT Y823D (Cancer Res 2015;75(15 Suppl):Abstract nr 2690). detail...
KIT N822K acute myeloid leukemia sensitive DCC-2618 Preclinical - Pdx Actionable In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring KIT N822K (Cancer Res 2015;75(15 Suppl):Abstract nr 2690). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02571036 Phase I DCC-2618 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Recruiting
NCT03673501 Phase III Sunitinib DCC-2618 A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue) Recruiting
NCT03353753 Phase III DCC-2618 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus) Active, not recruiting